Evidence map›Paper›PMID 42243186›Full record

ArticleScientific reports2026

Body placement of inertial measurement units differentially affects physical activity assessment accuracy in drug-naïve Parkinson's disease.

Corina Maetzler, Masoud Abedinifar, Vaishali Vinod, Julius Welzel, Eva Schaeffer, Rezzak Yilmaz, Markus A Hobert, Clint Hansen, Franck Durif, Jean-Christophe Corvol and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Corina Maetzler *Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Masoud Abedinifar *Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Vaishali VinodDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Julius WelzelDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Eva SchaefferDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Rezzak YilmazDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Markus A HobertDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Clint HansenDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Franck DurifDepartment of Neurology, CNRS, CHU Clermont-Ferrand, Institut Pascal, Université Clermont-Auvergne, 63001, Clermont-Ferrand, France.
Jean-Christophe CorvolDepartment of Neurology, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, NS-Park/FCRIN Network, Paris, France.
Olivier RascolDepartments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC1436, NS-Park/FCRIN Network, NeuroToul COEN Center, University Hospital of Toulouse, INSERM and University of Toulouse, Toulouse, France.
Stefanie BehnkeDepartment of Neurology, Klinik Sulzbach, Knappschaftsklinikum Saar, Sulzbach, Germany.
Werner PoeweDepartment of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.
Kirsten E ZeunerDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Evzen RuzickaCharles University and General University Hospital, Prague, Czechia.
Joaquim J FerreiraLaboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Robbin RomijndersDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Daniela BergDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
David DevosDepartment of Medical Pharmacology, Lille University, Lille Neurosciences and Cognition, INSERM 1172, CHU-Lille, NS-Park/FCRIN Clinical Research Network, Lille, France.
Caroline MoreauNeurology and Movement Disorders Department, Lille University, Lille Neurosciences and Cognition, INSERM 1172, CHU-Lille, NS-Park/FCRIN Clinical Research Network, Lille, France.
Franziska HopfnerDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany.
Walter MaetzlerDepartment of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany. w.maetzler@neurologie.uni-kiel.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) affects physical activity, and physical activity reduces the burden of PD. Although shown in studies using inertial measurement units (IMU), it remains unclear at which position physical activity change can best be detected in this population. Within the FAIRPARK-II trial, a subgroup of 25 newly diagnosed persons with PD (pwPD) not taking disease-specific medication yet documented their physical activity and, in parallel, wore IMUs on the most affected ankle, wrist and the lower back for two weeks. Participant-reported physical activity was transformed into Metabolic Equivalents of Tasks (METs) in 15-minute intervals using The Compendium of Physical Activities; Euclidean Norm Minus One (ENMO) values were calculated and averaged over the same intervals for the IMU data. Data of at least 3 days with at least four simultaneous 15-minute epochs of both valid IMU and diary data within the time window (9.00 to 18.00) per participant was included, resulting in a total of 8,494 15-minute epochs used for this analysis. Root mean square error (RMSE) values were calculated between scaled normalized IMU-derived ENMO and normalized MET values for each of the nine IMU-MET combinations (three IMU positions × three MET intensity levels). The wrist and lower back IMU showed comparable RMSE values across all MET intensity levels, with both IMU positions showing lower RMSE values than the ankle position. Tremor affected RMSE negatively, whereby the lower back position may be slightly favorable for the assessment of physical activity in those with tremor. This prospective longitudinal dataset from a very rare cohort provides novel insights into the assessment of physical activity during the earliest clinically evident phase of Parkinson's disease without disease-specific medication, which may inform future clinical trials and observational studies.

Indexed as

AccelerometryExerciseParkinson DiseaseAgedFemaleHumansMaleMiddle AgedDrug-naïve people with Parkinson’s diseaseEarly Parkinson’s diseaseENMOIMUMET

Identifiers

PMID42243186
PMCPMC13241497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.